Is Strategic Purchasing in Iranian Insurance Companies Effective?
Abstract
Since up to 60 percent of health care expenditures in developing countries are allocated to pharmaceutical products, utilizing this budget in order to supply pharmaceutical products is important. Good Procurement Practice (GPP) with the assistance of various ways of tendering is one of the most cost-effective methods in this matter. Studies showed that adding one extra supplier to tendering will cause 10 percent price reduction on average which is considered the most important outcome of tendering. In cases where there are many suppliers, tendering is recommended as a strong method in pricing and reimbursement. It seemed that GPP in reimbursement companies is not sufficient in Iran. Although bidding in countries that have developed in the generic markets is more common than those that are reaching this goal, it is recommended that reimbursement companies use bidding for inpatients, outpatients, specific patients and product groups, vaccines, and bulk products in cumulative and regional and national level. These would result in optimum use of the public budget.
[1] Maniadakis N, Holtorf AP, Otávio Corrêa J, Gialama F, Wijaya K. Shaping pharmaceutical tenders for effectiveness and sustainability in countries with expanding healthcare coverage. Appl Health Econ Health Policy. 2018; 16(5):591-607. [DOI:10.1007/s40258-018-0405-7] [PMID] [PMCID]
[2] Embrey MA. MDS-3: Managing access to medicines health technologies. 3rd ed. West Hartford: Kumarian Press; 2012. https://books.google.com/books?id=LgeUMQEACAAJ&dq
[3] Dranitsaris G, Jacobs I, Kirchhoff C, Popovian R, Shane LG. Drug tendering: Drug supply and shortage implications for the uptake of biosimilars. Clinicoecon Outcomes Res. 2017; 9:573-84. [DOI:10.2147/CEOR.S140063] [PMID] [PMCID]
[4] Wouters OJ, Sandberg DM, Pillay A, Kanavos PG. The impact of pharmaceutical tendering on prices and market concentration in South Africa over a 14-year period. Soc Sci Med. 2019; 220:362-70. [DOI:10.1016/j.socscimed.2018.11.029] [PMID]
[5] Petrou P, Talias MA. Price determinants of the tendering process for pharmaceuticals in the Cyprus market. Value Health Reg Issues. 2015; 7:67-73. [DOI:10.1016/j.vhri.2015.09.001] [PMID]
[6] Leopold C, Habl C, Vogler S. Tendering of pharmaceuticals in EU member states and EEA countries. Results from the country survey. Vienna: ÖBIG Forschungs-und Planungsgesellschaft mbH; 2008. https://ppri.goeg.at/sites/ppri.goeg.at/files/inline-files/Final_Report_Tendering_June_08_7.pdf
[7] Kanavos P, Seeley E, Vandoros S. Tender systems for outpatient pharmaceuticals in the European Union: Evidence from the Netherlands, Germany and Belgium. London: LSE Health London School of Economics; 2009. https://www.politico.eu/wp-content/uploads/2019/02/Tender-systems-for-outpatient-pharmaceuticalsin-
the-EU.pdf
[8] World Health Organization. [WHO medicines strategy: Framework for action in essential drugs and medicines policy 2000-2003 (English & French)] [Internet]. 2000. [Updated 2000]. Available from: https://apps.who.int/iris/handle/10665/66503
[9] Singh PV, Tatambhotla A, Kalvakuntla R, Chokshi M. Understanding public drug procurement in India: A comparative qualitative study of five Indian states. BMJ Open. 2013; 3(2):e001987. [DOI:10.1136/bmjopen-2012-001987] [PMID] [PMCID]
[2] Embrey MA. MDS-3: Managing access to medicines health technologies. 3rd ed. West Hartford: Kumarian Press; 2012. https://books.google.com/books?id=LgeUMQEACAAJ&dq
[3] Dranitsaris G, Jacobs I, Kirchhoff C, Popovian R, Shane LG. Drug tendering: Drug supply and shortage implications for the uptake of biosimilars. Clinicoecon Outcomes Res. 2017; 9:573-84. [DOI:10.2147/CEOR.S140063] [PMID] [PMCID]
[4] Wouters OJ, Sandberg DM, Pillay A, Kanavos PG. The impact of pharmaceutical tendering on prices and market concentration in South Africa over a 14-year period. Soc Sci Med. 2019; 220:362-70. [DOI:10.1016/j.socscimed.2018.11.029] [PMID]
[5] Petrou P, Talias MA. Price determinants of the tendering process for pharmaceuticals in the Cyprus market. Value Health Reg Issues. 2015; 7:67-73. [DOI:10.1016/j.vhri.2015.09.001] [PMID]
[6] Leopold C, Habl C, Vogler S. Tendering of pharmaceuticals in EU member states and EEA countries. Results from the country survey. Vienna: ÖBIG Forschungs-und Planungsgesellschaft mbH; 2008. https://ppri.goeg.at/sites/ppri.goeg.at/files/inline-files/Final_Report_Tendering_June_08_7.pdf
[7] Kanavos P, Seeley E, Vandoros S. Tender systems for outpatient pharmaceuticals in the European Union: Evidence from the Netherlands, Germany and Belgium. London: LSE Health London School of Economics; 2009. https://www.politico.eu/wp-content/uploads/2019/02/Tender-systems-for-outpatient-pharmaceuticalsin-
the-EU.pdf
[8] World Health Organization. [WHO medicines strategy: Framework for action in essential drugs and medicines policy 2000-2003 (English & French)] [Internet]. 2000. [Updated 2000]. Available from: https://apps.who.int/iris/handle/10665/66503
[9] Singh PV, Tatambhotla A, Kalvakuntla R, Chokshi M. Understanding public drug procurement in India: A comparative qualitative study of five Indian states. BMJ Open. 2013; 3(2):e001987. [DOI:10.1136/bmjopen-2012-001987] [PMID] [PMCID]
| Files | ||
| Issue | Vol 7 No 1/2 (2021) | |
| Section | Letter to Editor | |
| Keywords | ||
| Tendering Strategic purchasing Good Procurement Practice Insurance Price | ||
| Rights and permissions | |
|
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License. |
How to Cite
1.
Faraji H, Kebriaeezadeh A. Is Strategic Purchasing in Iranian Insurance Companies Effective?. JPPM. 2021;7(1/2):1-2.
